| 品牌 | 货号 | 产品规格 | 价格(RMB) | 库存（上海） | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
| 源叶(MedMol) | S85041-2mg | 99% | ￥100.00元 | 5 | - | - | - |
|
| 源叶(MedMol) | S85041-5mg | 99% | ￥200.00元 | 5 | - | - | - |
|
| 源叶(MedMol) | S85041-10mg | 99% | ￥350.00元 | 6 | - | - | - |
|
| 源叶(MedMol) | S85041-25mg | 99% | ￥500.00元 | 预计交期：2-3天 | - | - | - |
|
| 源叶(MedMol) | S85041-50mg | 99% | ￥800.00元 | 预计交期：2-3天 | - | - | - |
|
| 源叶(MedMol) | S85041-100mg | 99% | ￥1400.00元 | 预计交期：2-3天 | - | - | - |
|
| 产品描述： GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response | ||||||||||||||||||||
| 靶点： Free Fatty Acid Receptor;GPR | ||||||||||||||||||||
|
体外研究： GSK137647A (GSK 137647) (50 µM) reduces the production of NO in macrophages without affecting cell viability[1].GSK137647A (GSK 137647) (30 µM; 12 hours) alleviates response to inflammatory stimuli in Caco-2 cells and induces secretion of IL-6[1]. GSK137647A (GSK 137647) (10 µM) reduces the ion flow and affects the colonic epithelial ion transport in healthy. GSK137647A (GSK 137647) (50 µM) increases glucose stimulated insulin secretion. Western Blot Analysis Cell Line: Caco-2 cells Concentration: 30 µM Incubation Time: 12 hours Result: Downregulated FFAR1, FFAR2, and FFAR4 as compared to control. Cell Viability Assay Cell Line: RAW264.7 macrophages Concentration: 10, 20 and 50 µM Incubation Time: 24 hours Result: Without affected cell viability. |
||||||||||||||||||||
|
体内研究： GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) alleviates colitis in TNBS- and DSS-treated mice. GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) restores intestinal permeability in vivo. Animal Model: Male C57BL/6 mice Dosage: 1 mg/kg Administration: Intraperitoneal injection; twice daily, for 7 days Result: Had anti-inflammatory effect and reversed colonic injury induced by DSS. Animal Model: Male C57BL/6 mice Dosage: 1 mg/kg Administration: Intraperitoneal injection; twice daily, for 7 days Result: Decreased the amount of FITC and alleviated intestinal epithelial barrier permeability. |
||||||||||||||||||||
|
参考文献： 1. Salaga M, et, al. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. 2. Sparks SM, et, al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul 15;24(14):3100-3. |
||||||||||||||||||||
| 溶解性： Soluble in DMSO、H2O | ||||||||||||||||||||
| 保存条件： -20℃ | ||||||||||||||||||||
配置溶液浓度参考：
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
|---|
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京